jcm-logo

Journal Browser

Journal Browser

New Treatments for Inflammatory and Neoplastic Skin Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: closed (30 November 2024) | Viewed by 1495

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Physiopathology and Transplantation, University of Milan, 20122 Milan, Italy
2. Dermatology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy
Interests: melanoma; dermatology; dermatoscopy; hidradenitis suppurativa; acne
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the last 15 years, the advent of biologics has revolutionized the treatment of psoriasis. After the first anti-tnf-alfa drugs, biosimilars are also now available; the anti-interleukin groups (anti-IL-17 and anti-IL-23) are safe and effective treatments for most psoriatic patients, even those with difficult-to-treat body areas.

Furthermore, the management of atopic dermatitis has changed thanks to dupilumab and, subsequently, tralokinumab as well as the inhibitors of Janus kinases. In the near future, many other drugs, both biologics and small molecules, will be marketed for several skin diseases, including vitiligo, alopecia areata, and hidradenitis suppurativa.

In the field of dermato-oncology, immunotherapy and targeted therapies are currently used for difficult-to-treat locally advanced basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Sharing experiences of these treatments will enhance the knowledge and confidence of dermatologists.

An early diagnosis is crucial for the timely assessment of patients, so as to seek the best treatment plans and improve a patient's condition.

For this Special Issue, we expect reviews and original research on new approaches to the diagnosis and management of skin tumors. We welcome contributions that provide clinicians with the latest research advances and insights.

Dr. Gianluca Nazzaro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dermatology
  • dermatological diseases
  • skin
  • psoriasis
  • atopic dermatitis
  • hidradenitis suppurativa
  • alopecia areata
  • vitiligo
  • squamous cell carcinoma (SCC)
  • basal cell carcinoma (BCC)
  • melanoma
  • diagnostic
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 2632 KiB  
Article
Treatment of Sebaceous Hyperplasia by High-Frequency Focused Ultrasound (HIFU): A Comprehensive Exploration with Clinical Insights
by Bartosz Woźniak, Natalia Sauer, Anna Pogorzelska-Antkowiak, Piotr Dzięgiel and Jacek Calik
J. Clin. Med. 2025, 14(4), 1305; https://doi.org/10.3390/jcm14041305 - 16 Feb 2025
Viewed by 1057
Abstract
Background: Sebaceous hyperplasia (SH) is a common benign condition characterized by enlarged sebaceous glands, often requiring treatment for cosmetic or symptomatic reasons. Conventional therapies include laser ablation, electrosurgery, and cryotherapy, but these may be associated with discomfort, scarring, or recurrence. High-Frequency Focused Ultrasound [...] Read more.
Background: Sebaceous hyperplasia (SH) is a common benign condition characterized by enlarged sebaceous glands, often requiring treatment for cosmetic or symptomatic reasons. Conventional therapies include laser ablation, electrosurgery, and cryotherapy, but these may be associated with discomfort, scarring, or recurrence. High-Frequency Focused Ultrasound (HIFU) has emerged as a non-invasive alternative. This study evaluates the efficacy, safety, and patient acceptability of HIFU for the treatment of SH. Methods: Six patients with a total of 33 SH lesions underwent a single HIFU session at a frequency of 20 MHz. Lesion resolution was assessed clinically and dermatoscopically, while secondary outcomes included patient-reported pain levels and treatment-related side effects. Follow-up evaluations were conducted to determine therapeutic response and tolerability. Results: Post-treatment, 87.9% (n = 29) of lesions achieved complete resolution, while 12.1% (n = 4) demonstrated partial reduction in size. Patients reported minimal discomfort during the procedure, describing it as virtually painless. The side effect profile was favorable, with no significant adverse events recorded. Conclusions: HIFU at 20 MHz is an effective and well-tolerated treatment for SH, offering high rates of lesion clearance with minimal discomfort and a low risk of complications. These findings support the role of HIFU as a promising non-invasive alternative to traditional SH treatments, aligning with the trend toward less aggressive dermatological interventions. Further studies with larger cohorts and long-term follow-up are warranted to confirm these results. Full article
(This article belongs to the Special Issue New Treatments for Inflammatory and Neoplastic Skin Diseases)
Show Figures

Figure 1

Back to TopTop